Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.90 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377835 | 1.00 | NR1H2 (0.90) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL29507781 | 0.95 | NR1H2 (1.00) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL308035 | 0.95 | NR1H2 (1.00) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL4924112 | 0.92 | NR1H2 (0.77) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL2306894 | 0.92 | NR1H2 (0.85) | NR1H2ESR2MAPK1ADORA1HDAC6 | |
| SCHEMBL520400 | 0.89 | NR1H2 (0.80) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL29803773 | 0.89 | NR1H2 (0.80) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL13285564 | 0.88 | NR1H2 (0.70) | NR1H2ESR2MAPK1ABHD6HDAC1 | |
| SCHEMBL4928220 | 0.87 | NR1H2 (0.85) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL450677 | 0.85 | ESR2 (1.00) | NR1H2ESR2MAPK1ABHD6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-2026086915-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR (GIPR) ANTAGONISTS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | NR1H2 1727/4885ESR2 2699/4885MAPK1 1134/4885 |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | NR1H2 743/4885ESR2 2379/4885MAPK1 235/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | NR1H2 1279/4885ESR2 1137/4885MAPK1 4265/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | NR1H2 1257/4885ESR2 2535/4885MAPK1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.